参一胶囊联合NP方案治疗晚期非小细胞肺癌的临床观察  

Ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer

作　　者：刘素勤[1] 孙亮新[1] 班丽英[1] 周涛[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科

出　　处：《临床肿瘤学杂志》2007年第11期847-849,共3页Chinese Clinical Oncology

摘　　要：目的:观察参一胶囊(人参皂甙Rg3)联合去甲长春花碱与顺铂方案(NP方案)化疗治疗晚期非小细胞肺癌的疗效、毒副反应及细胞免疫功能变化。方法:观察组35例患者给予参一胶囊20mg每日2次口服,自化疗前3天开始用药至化疗停药后7天止,共39天。对照组35例给予NP方案化疗。均化疗2周期后评价疗效。应用流式细胞仪检测细胞免疫指标。结果:观察组有效率37.1%(13/35),对照组有效率31.4%(11/35),两组疗效未见差异(P>0.05);观察组白细胞减少发生率低于对照组(P<0.05);观察组卡氏评分较对照组改善明显(P<0.05);观察组CD4/CD8比值及NK阳性细胞百分率治疗后提高,差异有显著性(P<0.05)。结论:参一胶囊联合NP方案治疗晚期非小细胞肺癌白细胞减少发生率低,并可改善行为状况,提高患者细胞免疫功能。Objective：To evaluate the clinical efficacy, side effect and cytoimmunity function of ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer. Methods： Thirty-five patients received ginsenoside Rg3 capsules 20mg bid po for 39 days plus domestic vinorelbine 25mg/m^2 d1, d8 and Cisplatin 25mg/m^2 d1-d3 , q3w for 2 cycles. Thirtyfive patients received domestic vinorelbine and Cisplatin only as control group. Results：For observed group and control group, the re- sponse rate of those was 37. 1% and 31.4%, respectively and the toxicity leucopenia was 65.7% and 88. 6% （P 〈0. 05） ; KPS scale was improved in study group （ P 〈 0. 05 ） ; the improvement of CD4/CD8 ratio and NK positive cell ratio is observed in the study group （ P 〈 0. 05 ）. Conclusion ： Ginsenoside Rg3 capsules combined NP regimen is effective in the treatment of advanced non-small cell lung cancer, and ginsenoside Rg3 capsules can decrease the occurring of leucopenia, improve KPS scale and the cytoimmunity function.

关 键 词：参一胶囊/人参皂甙Rg3 非小细胞肺癌 化学治疗 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]